ARTICLE | Top Story

Cephalon meets Street

August 3, 2004 7:00 AM UTC

CEPH reported second quarter EPS of $0.39, meeting the Street estimate and up 30% from $0.30 in the second quarter last year. CEPH's earnings exclude a $30.1 million impairment charge associated with a write-off of its investment in MDS Proteomics, which restructured in June. Second quarter sales were $235 million, up from $160.3 million quarter over quarter. Sales of narcolepsy and sleep disorder drug Provigil were up 48% to $102.8 million. Sales of Actiq fentanyl for breakthrough cancer pain were up 63% to $85.6 million, and sales of epilepsy drug Gabitril tiagabine increased 70% to $24.7 million. ...